{"id":"https://openalex.org/W1550197841","doi":null,"title":"Inhibitory effects of prostaglandin A2 on c-myc expression and cell cycle progression in human leukemia cell line HL-60.","display_name":"Inhibitory effects of prostaglandin A2 on c-myc expression and cell cycle progression in human leukemia cell line HL-60.","publication_year":1988,"publication_date":"1988-05-15","ids":{"openalex":"https://openalex.org/W1550197841","mag":"1550197841","pmid":"https://pubmed.ncbi.nlm.nih.gov/3162825"},"language":"en","primary_location":{"id":"pmid:3162825","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/3162825","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000947818","display_name":"Chikashi Ishioka","orcid":"https://orcid.org/0000-0002-3023-1227","observed_orcids":["https://orcid.org/0000-0002-3023-1227"]},"institutions":[{"id":"https://openalex.org/I201537933","display_name":"Tohoku University","ror":"https://ror.org/01dq60k83","country_code":"JP","type":"education","lineage":["https://openalex.org/I201537933"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"C Ishioka","raw_affiliation_strings":["Department of Clinical Cancer Chemotherapy, Tohoku University, Sendai, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Cancer Chemotherapy, Tohoku University, Sendai, Japan","institution_ids":["https://openalex.org/I201537933"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110076460","display_name":"Ryunosuke Kanamaru","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R Kanamaru","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089185800","display_name":"Takao Sato","orcid":"https://orcid.org/0000-0001-5575-4086","observed_orcids":["https://orcid.org/0000-0001-5575-4086"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Sato","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091624513","display_name":"Toshio Dei","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Dei","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109321768","display_name":"Y Konishi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y Konishi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001397527","display_name":"M Asamura","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Asamura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5003589367","display_name":"A Wakui","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A Wakui","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.2687,"has_fulltext":false,"cited_by_count":47,"citation_normalized_percentile":{"value":0.86635767,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"48","issue":"10","first_page":"2813","last_page":"8"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.8471999764442444,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.8471999764442444,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.06210000067949295,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.015799999237060547,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/prostaglandin-a2","display_name":"prostaglandin A2","score":1.0},{"id":"https://openalex.org/keywords/c-myc-expression","display_name":"c-myc expression","score":0.9200000166893005},{"id":"https://openalex.org/keywords/hl-60-cells","display_name":"HL-60 cells","score":0.8980000019073486},{"id":"https://openalex.org/keywords/promyelocytic-leukemia","display_name":"promyelocytic leukemia","score":0.9919999837875366},{"id":"https://openalex.org/keywords/cell-cycle-arrest","display_name":"cell cycle arrest","score":0.9559999704360962},{"id":"https://openalex.org/keywords/g0-g1-phase","display_name":"G0/G1 phase","score":0.8920000195503235},{"id":"https://openalex.org/keywords/c-myc-mrna","display_name":"c-myc mRNA","score":0.7630000114440918},{"id":"https://openalex.org/keywords/growth-inhibition","display_name":"growth inhibition","score":0.7139999866485596},{"id":"https://openalex.org/keywords/cycloheximide","display_name":"cycloheximide","score":0.6899999976158142},{"id":"https://openalex.org/keywords/prostaglandin-degradation","display_name":"prostaglandin degradation","score":0.5979999899864197}],"concepts":[{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.7068684697151184},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.5807742476463318},{"id":"https://openalex.org/C2778128677","wikidata":"https://www.wikidata.org/wiki/Q412895","display_name":"Cycloheximide","level":3,"score":0.5704652070999146},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.535454273223877},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.5023612976074219},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.49408605694770813},{"id":"https://openalex.org/C2780664492","wikidata":"https://www.wikidata.org/wiki/Q209717","display_name":"Prostaglandin","level":2,"score":0.4719765782356262},{"id":"https://openalex.org/C105696609","wikidata":"https://www.wikidata.org/wiki/Q1068809","display_name":"Cell cycle checkpoint","level":4,"score":0.41067689657211304},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.3831869959831238},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.20334747433662415},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.06070777773857117}],"mesh":[{"descriptor_ui":"D002453","descriptor_name":"Cell Cycle","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002455","descriptor_name":"Cell Division","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003513","descriptor_name":"Cycloheximide","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D005434","descriptor_name":"Flow Cytometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006680","descriptor_name":"HLA Antigens","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011454","descriptor_name":"Prostaglandins A","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011457","descriptor_name":"Prostaglandins D","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011519","descriptor_name":"Proto-Oncogenes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D014407","descriptor_name":"Tumor Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015230","descriptor_name":"Prostaglandin D2","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:3162825","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/3162825","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Journal Article"},{"id":"mag:1550197841","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/3162825","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2055624149","https://openalex.org/W2031889681","https://openalex.org/W1980456945","https://openalex.org/W1979252983","https://openalex.org/W1964730992","https://openalex.org/W2069556343","https://openalex.org/W2112597357","https://openalex.org/W2067051181","https://openalex.org/W2128931853","https://openalex.org/W2372885725"],"abstract_inverted_index":{"The":[0,160],"effect":[1],"of":[2,47,62,64,73,91,108,119,136,142,163,173,185,187,206,216],"prostaglandin":[3],"A2":[4],"(PGA2)":[5],"on":[6,103],"c-myc":[7,48,92,104,174,217],"expression":[8,105],"was":[9,82,93,167,175,211],"investigated":[10],"in":[11,132,145,189,202],"a":[12,24],"human":[13],"promyelocytic":[14],"leukemia":[15],"cell":[16,138,165,208],"line,":[17],"HL-60,":[18],"which":[19],"responded":[20],"to":[21,38,59,69,122,182],"PGA2":[22,35,86,101,123,188,197],"with":[23,34,213],"dose-dependent":[25],"growth":[26],"inhibition.":[27],"Northern":[28],"blot":[29],"analysis":[30,114],"indicated":[31],"that":[32,99,116,196],"treatment":[33,198],"at":[36,124,154],"0.5":[37,125,155],"5.0":[39,127,157],"micrograms/ml":[40,128],"remarkably":[41],"reduced":[42],"the":[43,60,65,71,117,130,133,137,143,164,171,183,203,207,214],"steady":[44],"state":[45],"level":[46,72],"mRNA":[49],"within":[50],"3":[51],"h,":[52],"and":[53,210],"then":[54],"it":[55],"gradually":[56],"recovered":[57,169],"according":[58],"order":[61],"concentration":[63],"drug.":[66],"In":[67],"contrast":[68],"c-myc,":[70],"class":[74],"I":[75],"HLA":[76],"mRNA,":[77],"as":[78,170],"an":[79],"internal":[80],"control,":[81],"not":[83,94],"diminished":[84],"by":[85,96],"treatment.":[87],"Further,":[88],"this":[89,100],"reduction":[90,215],"disturbed":[95],"cycloheximide,":[97],"suggesting":[98],"action":[102],"is":[106],"independent":[107],"de":[109],"novo":[110],"protein":[111],"synthesis.":[112],"Cytofluorometric":[113],"revealed":[115],"exposure":[118],"HL-60":[120,200],"cells":[121,131,144,201],"or":[126,151,156],"arrested":[129,199],"G0-G1":[134,146,161,204],"phase":[135,147,205],"cycle.":[139],"This":[140,177,192],"accumulation":[141],"continues":[148],"until":[149],"24":[150],"36":[152],"h":[153],"micrograms/ml,":[158],"respectively.":[159],"arrest":[162],"cycle":[166,209],"also":[168],"inhibition":[172],"released.":[176],"recovery":[178],"may":[179],"be":[180],"due":[181],"loss":[184],"activity":[186],"culture":[190],"medium.":[191],"study":[193],"clearly":[194],"showed":[195],"associated":[212],"mRNA.":[218]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}